Target intelligence / Profile preview

Heme crystallization (Plasmodium falciparum) (None)

Target
None
Molecular classification
Metabolic pathway, Non-protein target, Biocrystallization process
01

Overview

Heme crystallization is a critical detoxification process in the malaria parasite Plasmodium falciparum, occurring within its acidic digestive vacuole (Coronado et al., 2014, Toxins). During the intraerythrocytic stage, the parasite catabolizes host hemoglobin to obtain essential amino acids, a process that releases large amounts of ferriprotoporphyrin IX (free heme), which is highly toxic to the parasite (Sullivan, 2002, Int J Parasitol). To survive, the parasite polymerizes this free heme into an insoluble, chemically inert crystalline form known as hemozoin, or malaria pigment (Egan, 2008, J Inorg Biochem). This crystallization process is the primary target for several classes of antimalarial drugs, most notably the quinolines such as chloroquine and quinine. These drugs interfere with the formation of hemozoin by binding to heme or the crystal growth face, leading to the accumulation of toxic free heme and subsequent parasite death (Huy et al., 2002, J Biol Chem). Despite its historical success as a target, the emergence of resistance—primarily through mutations in the Plasmodium falciparum chloroquine resistance transporter (PfCRT)—remains a significant challenge in malaria treatment.

Other names
Hemozoin formationHeme detoxificationFerriprotoporphyrin IX polymerizationBeta-hematin formationMalaria pigment formation
02

Mechanism of action

Inhibition of the biocrystallization of toxic ferriprotoporphyrin IX into non-toxic hemozoin crystals within the parasite food vacuole (Sullivan, 2002, Int J Parasitol).

03

Biological functions

DetoxificationMetabolic processHeme sequestration
04

Disease associations

InfectionMalaria
05

Safety considerations

Drug resistance mediated by PfCRT mutationsCardiotoxicity (QT prolongation associated with quinolines)Retinopathy (associated with long-term chloroquine use)Neuropsychiatric effects (associated with mefloquine)
06

Interacting drugs

Chloroquine

7 more in the full profile.

07

Biomarkers

Hemozoin (malaria pigment) levelsParasitemia (parasite count in blood)PfCRT (Plasmodium falciparum chloroquine resistance transporter) mutationsLactate dehydrogenase (pLDH) levels

Beyond the preview

Go deeper on Heme crystallization (Plasmodium falciparum) (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heme crystallization (Plasmodium falciparum) (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call